USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended July 2, 2022.
Second quarter net sales were $264 million as compared with $337 million during the second quarter of the prior year.
Second quarter diluted EPS totaled $1.00 versus $1.87 during the second quarter of 2021.
Company reiterates fiscal 2022 net sales and diluted EPS outlook of $1.015 billion to $1.065 billion and $3.85 to $4.45, respectively.
“As indicated in our preliminary results release on July 6th, we continue to experience COVID-related disruptions in several key markets, including mainland China. This caused participation in sales programs, Active Customer counts, and financial performance to come in lower than anticipated,”
said Kevin Guest, Chief Executive Officer and Chairman of the Board.
“Although many of these disruptions were outside of our control, and while we faced a tough year-over year comparable due to the timing of a successful sales program in 2021, our second quarter results were not up to our standards.
Nevertheless, we remain committed to our business strategy which we believe will deliver sustained, long-term growth in customer counts, net sales, and EPS.
Important elements of this strategy include
enhancing digital experience for our customers to improve the overall online shopping experience;
improving